Last reviewed · How we verify

Edaravone dexborneol sublingual tablet

Simcere Pharmaceutical Co., Ltd · Phase 2 active Small molecule

Edaravone dexborneol sublingual tablet is a Small molecule drug developed by Simcere Pharmaceutical Co., Ltd. It is currently in Phase 2 development.

At a glance

Generic nameEdaravone dexborneol sublingual tablet
SponsorSimcere Pharmaceutical Co., Ltd
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Edaravone dexborneol sublingual tablet

What is Edaravone dexborneol sublingual tablet?

Edaravone dexborneol sublingual tablet is a Small molecule drug developed by Simcere Pharmaceutical Co., Ltd.

Who makes Edaravone dexborneol sublingual tablet?

Edaravone dexborneol sublingual tablet is developed by Simcere Pharmaceutical Co., Ltd (see full Simcere Pharmaceutical Co., Ltd pipeline at /company/simcere-pharmaceutical-co-ltd).

What development phase is Edaravone dexborneol sublingual tablet in?

Edaravone dexborneol sublingual tablet is in Phase 2.

Related